NewAmsterdam Pharma Co N.V annual revenue
2022
2023
2024
2025
NewAmsterdam Pharma Co N.V Revenue Growth & History (NAMS)
NewAmsterdam Pharma Co N.V reported $22.5M in revenue for fiscal 2025, a decrease of 50.61% from the previous fiscal year.
View full NewAmsterdam Pharma Co N.V company overviewNewAmsterdam Pharma Co N.V annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $22.5M | −$23.1M | −50.61% |
| 2024 | 2024-12-31 | $45.6M | $31.5M | +223.37% |
| 2023 | 2023-12-31 | $14.1M | −$88.6M | −86.28% |
| 2022 | 2022-12-31 | $102.7M | — | — |
NewAmsterdam Pharma Co N.V quarterly revenue
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.7M | −$15.4M | −80.67% |
| Q1 2026 | 2026-03-31 | $3.0M | $62,000 | +2.08% |
| Q4 2025 | 2025-12-31 | $32,000 | −$12.7M | −99.75% |
| Q3 2025 | 2025-09-30 | $348,000 | −$28.8M | −98.80% |
| Q2 2025 | 2025-06-30 | $19.1M | $16.9M | +740.06% |
| Q1 2025 | 2025-03-31 | $3.0M | $1.6M | +112.56% |
| Q4 2024 | 2024-12-31 | $12.8M | $12.0M | +1490.54% |
| Q3 2024 | 2024-09-30 | $29.1M | $26.2M | +889.83% |
| Q2 2024 | 2024-06-30 | $2.3M | $562,000 | +32.73% |
| Q1 2024 | 2024-03-31 | $1.4M | −$7.2M | −83.76% |
| Q4 2023 | 2023-12-31 | $803,000 | — | — |
| Q3 2023 | 2023-09-30 | $2.9M | — | — |
| Q2 2023 | 2023-06-30 | $1.7M | — | — |
| Q1 2023 | 2023-03-31 | $8.6M | — | — |
NewAmsterdam Pharma Co N.V revenue growth trends
NewAmsterdam Pharma Co N.V's latest reported quarter, Q2 2026, generated $3.7M in revenue, a decrease of 80.67% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review NewAmsterdam Pharma Co N.V source filings ↗